The enhancement of bactericidal activity by phagocytic macrophages without causing an increase in the overproduction of proinflammatory cytokines is also an attractive strategy against AKI, and C-reactive protein (CRP), an acute-phase protein that is produced in response to infection, inflammation, or organ damage, and is widely used as a marker of the inflammatory response, may be a candidate therapeutic molecule with such functions. This evidence concerns the gene CRP and infection.